NDAINTRAVENOUSSOLUTIONPriority Review
Approved
Jun 2010
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
60
Data completeness
4/8 — Partial
Priority Review
Drug data last refreshed 16h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
JEVTANA KIT is a small-molecule taxane chemotherapy agent containing cabazitaxel, approved for intravenous administration as a solution. It is indicated for metastatic castration-resistant prostate cancer (mCRPC) in patients previously treated with docetaxel. Cabazitaxel works by stabilizing microtubules and interfering with cell division, inducing apoptosis in cancer cells.
Peak4.6 years to LOE
JEVTANA is at peak commercial maturity with high competitive pressure (8/10), suggesting mature sales teams focused on market defense and efficiency rather than launch expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (60)
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)
Started Dec 2024
707 enrolled
Metastatic Castration-resistant Prostate Cancer
Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer
Started Dec 2020
120 enrolled
Aggressive Variant Prostate CarcinomaCastration-Resistant Prostate CarcinomaMetastatic Prostate Carcinoma+3 more
A Study of AZD4635 With Durvalumab and With Cabazitaxel and Durvalumab in Patients With mCRPC.
Started Aug 2020
30 enrolled
Progressive Metastatic Castrate-Resistant Prostate Cancer
Docetaxel Versus Cabazitaxel Post Abiraterone or Enzalutamide
Started Apr 2019
57 enrolled
Metastatic Prostate Cancer
Cabazitaxel and Prednisone in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Started Dec 2017
2 enrolled
Hormone-Resistant Prostate CancerStage IV Prostate Adenocarcinoma
Worked on JEVTANA KIT at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.